Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

COEP

Z Squared Inc

Apr 24 • 04:00PM ET

16.40

0.00 0.00 %

Healthcare • Biotechnology • USA • Micro • NASD

Peers: GILD REGN PFE MRNA BNTX JNJ VRTX AZN-D AMGN LLY

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.80	Insider Own	39.53%	Shs Outstand	5.75M	Perf Week	-
Market Cap	87.06M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	3.76M	Perf Month	56.79%
Enterprise Value	81.49M	PEG	-	EPS next Q	-	Inst Own	7.59%	Short Float	11.43%	Perf Quarter	24.15%
Income	-10.91M	P/S	64.01	EPS this Y	-	Inst Trans	15.46%	Short Ratio	8.07	Perf Half Y	6.29%
Sales	1.36M	P/B	5.46	EPS next Y	-	ROA	-70.73%	Short Interest	0.43M	Perf YTD	15.09%
Book/sh	3.00	P/C	13.71	EPS next 5Y	-	ROE	-96.83%	52W High	21.41 -23.40%	Perf Year	31.52%
Cash/sh	1.20	P/FCF	-	EPS past 3/5Y	62.31% 40.22%	ROIC	-62.70%	52W Low	6.26 161.98%	Perf 3Y	-35.43%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-207.81%	Volatility	8.99% 8.52%	Perf 5Y	-91.69%
Dividend TTM	-	EV/Sales	59.92	EPS Y/Y TTM	50.41%	Oper. Margin	-956.94%	ATR (14)	1.09	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.16	Sales Y/Y TTM	-	Profit Margin	-800.38%	RSI (14)	72.10	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.16	EPS Q/Q	80.71%	SMA20	27.37%	Beta	-0.04	Target Price	80.00
Payout	-	Debt/Eq	0.02	Sales Q/Q	-	SMA50	33.77%	Rel Volume	0.00	Prev Close	16.40
Employees	6	LT Debt/Eq	0.01	Earnings	-	SMA200	20.77%	Avg Volume	53.23K	Price	16.40
IPO	Dec 17, 2020	Option/Short	No / No	EPS/Sales Surpr.	- -	Trades		Volume	111,929	Change	0.00%

Apr-24-26 04:43PM	Z Squared Announces Completion of Business Combination with Coeptis Therapeutics and Listing on the Nasdaq Global Market (PR Newswire)
Apr-07-26 12:05PM	Coeptis Announces Approval of Z Squared Inc.'s Nasdaq Listing Application (GlobeNewswire) -10.52%
Feb-05-26 04:00PM	Coeptis Receives Shareholder Approval Towards Z Squared Merger (GlobeNewswire) -19.68% +6.22%
Jan-30-26 11:28AM	CSG Systems International Extraordinary General Meeting: Shareholders Back Key Proposals, Merger Actions (MarketBeat)
Jan-06-26 08:19AM	Coeptis Therapeutics S-4 Declared Effective by SEC, Proxy Mailing Begins in Anticipation of the Merger Transaction with Z Squared (GlobeNewswire)
08:00AM	Loading…
Sep-23-25 08:00AM	Vanderbilt Report: Coeptis Shows How Biotech Can Fund Itself While Innovating (GlobeNewswire) +13.41%
Jul-22-25 08:36AM	Coeptis (COEP) Extinguishes Convertible Note with YA II PN, Ltd (GlobeNewswire)
Jun-26-25 08:34AM	Coeptis (COEP) Announces Filing of Registration Statement on Form S-4 with SEC in Connection with Proposed Transaction with Z Squared (GlobeNewswire)
May-28-25 08:28AM	Monarch Therapeutics and SNAP Biosciences, Inc., a Subsidiary of Coeptis Therapeutics Holdings Inc., Enter Licensing Agreement to Bolster SNAP-CAR NK Cell Therapy in Oncology (GlobeNewswire)
May-12-25 08:20AM	NUBURU Files $100M SEC Registration Statement to Enhance Capital Flexibility for Completion of Defense Acquisition and Blue Laser Technology Revitalization Targeting a $500B Defense Market (Business Wire)
Apr-25-25 08:33AM	Coeptis Therapeutics, Inc. and Z Squared Inc. Announce Merger Agreement (GlobeNewswire) -38.25%
Apr-17-25 08:38AM	COEPTIS Partners with NexGenAI Solutions Group to Launch New AI Co-Working Hub in India, Driving Global Innovation in Technology (GlobeNewswire) +7.82%
Apr-15-25 08:33AM	NUBURU Announces Strategic Corporate Update Focused on Defense & Security, Advanced Technologies, and Growth Initiatives (Business Wire)
Mar-11-25 08:34AM	Coeptis Therapeutics Secures Worldwide Development and Commercialization Rights to Next-Generation GEAR Cell Therapy Platform Strengthening its High-Impact Precision Immuno-Oncology Pipeline (GlobeNewswire)
Mar-07-25 08:37AM	COEPTIS' NexGenAI Affiliates Partners with NUBURU Network to Drive Innovation in AI and Robotics as Part of its Transformation Plan (GlobeNewswire)
08:00AM	Loading…
Mar-06-25 08:00AM	NUBURU Partners With COEPTIS NexGenAI Affiliates Network to Drive Innovation in AI and Robotics as Part of Its Transformation Plan (Business Wire) -5.09%
Feb-20-25 09:00AM	COEPTIS' NexGenAI Partners with Arketyp Valu to Revolutionize Digital Engagement on the Verus Network (GlobeNewswire) -16.44%
07:27AM	COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing (GlobeNewswire)
Feb-19-25 04:00PM	COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing (GlobeNewswire)
Feb-13-25 08:39AM	COEPTIS Announces the Launch of COEP Venture Group to Invest in AI, RPA, and AI Agent Startups (GlobeNewswire)
Feb-06-25 08:08AM	COEPTIS Completes $10 Million Series A Preferred Financing Round, Reinforcing Commitment to Technological Innovation and AI Integration (PR Newswire)
Jan-30-25 08:27AM	Coeptis Therapeutics Holdings Becomes COEPTIS: Embracing a Future of Technology and Innovation (PR Newswire)
Jan-23-25 08:09AM	Coeptis Therapeutics Leverages Artificial Intelligence and Blockchain for Next-Generation Innovation (PR Newswire) -9.81%
Jan-22-25 08:00AM	Coeptis Therapeutics Regains Compliance with Nasdaq Listing Rule 5550(a)(2) (PR Newswire) +13.56%
Jan-07-25 08:00AM	Coeptis Therapeutics Announces First Customer Adoptions of its NexGenAI Marketing Platform (PR Newswire)
Dec-27-24 08:15AM	Coeptis Therapeutics Announces Reverse Stock Split (PR Newswire) -13.65%
Dec-26-24 08:15AM	Coeptis Therapeutics Makes Bold Strides in Innovation with the Acquisition of NexGenAI Affiliates Network Platform and Launch of Coeptis Technologies (PR Newswire) +48.59%
Dec-12-24 08:00AM	Coeptis Therapeutics Unveils New Technology Division: Coeptis Technologies (PR Newswire)
Dec-03-24 08:15AM	Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries (PR Newswire) +17.51%
Nov-07-24 08:07AM	Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development (PR Newswire)
08:07AM	Loading…
Oct-24-24 08:07AM	Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency Use (PR Newswire) -6.64%
Oct-15-24 08:07AM	Coeptis Therapeutics' Chief Scientific and Medical Officer to Present at Upcoming Fall Conferences, Highlighting Progress in Universal Cell Therapy (PR Newswire)
Sep-19-24 07:07AM	Coeptis Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing (PR Newswire) +5.47%
Sep-05-24 08:07AM	Coeptis Therapeutics Chief Executive Officer, Dave Mehalick, Updates and Outlines Strategic Vision in Letter to Shareholders (PR Newswire) -5.66%
Aug-16-24 08:52PM	COEP Stock Earnings: Coeptis Therapeutics Reported Results for Q2 2024 (InvestorPlace) +5.15%
Jun-20-24 08:47AM	Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering (PR Newswire) -8.81%
May-30-24 08:47AM	Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting (PR Newswire)
May-13-24 09:53AM	COEP Stock Earnings: Coeptis Therapeutics Reported Results for Q1 2024 (InvestorPlace) -7.07%
May-08-24 08:47AM	Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024 (PR Newswire)
May-02-24 08:47AM	Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting (PR Newswire) +8.77%
Apr-02-24 08:47AM	Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award (PR Newswire) +6.68%
Feb-26-24 09:00AM	Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK (PR Newswire) +9.89%
Feb-07-24 07:30AM	Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections (PR Newswire)
Jan-04-24 07:30AM	Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024 (PR Newswire) -10.71%
Dec-06-23 07:00AM	Presenting on the Emerging Growth Conference 65 Day 2 on December 7th Register Now (GlobeNewswire) -7.02%
Dec-05-23 07:00AM	Presenting on the Emerging Growth Conference 65 Day 1 on December 6th Register Now (GlobeNewswire) -5.00%
Dec-04-23 07:30AM	Coeptis Therapeutics to Present at the Emerging Growth Conference (PR Newswire)
Oct-31-23 09:01AM	Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023 (PR Newswire) -9.74%
07:00AM	Presenting on the Emerging Growth Conference 64 Day 1 on November 1 Register Now (GlobeNewswire)
Oct-24-23 08:30AM	Coeptis Therapeutics Announces $2 Million Private Placement (PR Newswire)
Oct-11-23 07:30AM	Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology (PR Newswire)
Oct-09-23 09:15AM	Coeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene Therapies (PR Newswire)
Oct-04-23 07:30AM	Coeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual Meeting (PR Newswire)
Oct-03-23 07:00AM	Presenting on the Emerging Growth Conference 63 Day 1 on October 4 Register Now (GlobeNewswire)
Sep-27-23 07:30AM	Coeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the Mesa (PR Newswire) +10.31%
Sep-14-23 07:30AM	Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection (PR Newswire)
Sep-11-23 07:30AM	Coeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington's Cancer Research Endowment (PR Newswire) -5.29%
Aug-30-23 01:00PM	Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer (PR Newswire)
Aug-17-23 07:30AM	Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics (PR Newswire)
Aug-01-23 08:00AM	Coeptis Therapeutics Files FDA 513(g) Submission for CD38 In Vitro Companion Diagnostic (PR Newswire)
Jun-16-23 04:00PM	Coeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten Offering (PR Newswire) -5.59%
Jun-14-23 09:28AM	Coeptis Therapeutics Holdings, Inc. Announces Pricing of $3.5 Million Underwritten Offering (PR Newswire) +6.06%
Jun-09-23 07:00AM	Coeptis Therapeutics Receives Approval to Transfer to The Nasdaq Capital Market (PR Newswire)
May-17-23 08:30AM	Coeptis Therapeutics Appoints Brian Cogley as Chief Financial Officer (PR Newswire)
May-10-23 03:00PM	Coeptis Therapeutics' SNAP-CAR Technology Platform for Programmable Antigen Targeting Featured in Peer-Reviewed Article in Nature Communications (PR Newswire)
Apr-18-23 07:30AM	Coeptis Therapeutics Signs Agreement to Acquire Allogeneic Immuno-Oncology NK Platform in Phase 1 Clinical Trials from Deverra Therapeutics (PR Newswire) +9.16%
Mar-29-23 09:45AM	Coeptis Therapeutics Secures Exclusive Rights to Negotiate to Acquire Transformational Cell Therapy Platform to Enable Potent Combinatorial Immuno-Oncology Treatment Strategies (PR Newswire)
Mar-21-23 07:00AM	Coeptis Therapeutics' SNAP-CAR Technology Platform Highlighted in Peer-Reviewed Article in Translational Medicine (PR Newswire)
Feb-07-23 08:00AM	Coeptis Therapeutics and ShareIntel Enter Shareholder Service Agreement, Targeting Illegal Short Selling (PR Newswire)
Jan-31-23 07:30AM	Coeptis Therapeutics Enters into Sponsored Research Agreement with the University of Pittsburgh to Advance SNAP-CAR Development Program (PR Newswire) +12.73%
Nov-22-22 07:00AM	Coeptis Therapeutics Engages IQVIA to Support SNAP-CAR Development Program (PR Newswire) -6.17%
Nov-15-22 07:00AM	Coeptis Therapeutics Holdings to Ring the Nasdaq Stock Market Opening Bell (PR Newswire)
Nov-08-22 07:00AM	Coeptis Therapeutics' Scientific Advisory Board Members Featured on "Biology of Natural Killer (NK) Cells" Podcast (PR Newswire) -17.13%
Nov-02-22 07:00AM	Coeptis Therapeutics Holdings Expands Board of Directors with New Appointments (PR Newswire) -8.81%
Sep-21-22 07:00AM	Coeptis Therapeutics Enters Exclusive License Agreement with University of Pittsburgh for Rights to SNAP-CAR, a "Multi-Antigen" CAR T Technology (PR Newswire)
May-17-22 07:00AM	Coeptis Therapeutics Enters into Exclusive Option Agreement with University of Pittsburgh for Rights to CAR-T Technologies Designed to Target Multiple Cancer Indications, Including Hematologic and Solid Tumors (PR Newswire)
Apr-19-22 07:00AM	Coeptis Therapeutics, Inc. and Bull Horn Holdings Corp. Announce Merger Agreement (PR Newswire)
Apr-13-22 04:05PM	Statera Biopharma and Coeptis Therapeutics Announce Strategic Agreement for Rights to Entolimod (GlobeNewswire)
07:00AM	Coeptis Therapeutics Announces Intent to Acquire TLR5 Agonist Platform, Including Clinical-Stage Asset Entolimod, from Statera Biopharma (PR Newswire)
Jan-20-22 08:00AM	Coeptis Therapeutics Establishes Scientific Advisory Board to Advance Cell Therapy Product Development (PR Newswire)

Operates as a digital asset mining company

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Yerace Daniel Alexander	Director	Apr 16 '26	Proposed Sale	12.82	5,000	64,100		Apr 16 11:53 AM
Cogley Brian	Chief Financial Officer	Feb 11 '26	Option Exercise	10.56	10,000	105,600	22,500	Feb 13 05:00 PM
Deschamps Philippe	Director	Feb 11 '26	Option Exercise	10.56	5,700	60,192	8,950	Feb 13 05:00 PM
Calise Chris	Director	Feb 11 '26	Option Exercise	10.56	5,700	60,192	368,741	Feb 13 05:00 PM
Mehalick David	CEO and President	Feb 11 '26	Option Exercise	7.05	148,875	1,049,569	330,192	Feb 13 05:00 PM
Cochran Christopher P.	Director	Feb 11 '26	Option Exercise	10.56	5,700	60,192	8,950	Feb 13 05:00 PM
Yerace Daniel Alexander	VP Operations	Feb 11 '26	Option Exercise	10.41	10,000	104,100	70,531	Feb 13 05:00 PM
Salkind Gene	Director	Feb 11 '26	Option Exercise	10.56	5,700	60,192	13,161	Feb 13 05:00 PM
DeSilva Tara	Director	Feb 11 '26	Option Exercise	10.56	5,700	60,192	8,950	Feb 13 05:00 PM
Sheehy Christine Elise	VP Compliance and Secy	Feb 11 '26	Option Exercise	10.56	1,000	10,560	64,031	Feb 13 05:00 PM
Yerace Daniel Alexander	Director	Dec 15 '25	Proposed Sale	15.02	5,000	75,100		Dec 15 11:26 AM
Yerace Daniel Alexander	Director	Sep 02 '25	Proposed Sale	12.96	5,000	64,800		Sep 02 10:04 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

COEP

Z Squared Inc

Upgrade your Finviz experience